LATEST NEWS

Uromedica at AUA 2023

Come visit Uromedica at the American Urological Association's 2023 Annual Meeting (AUA) , Booth 4025, April 28-1st

Uromedica at EAU 2023

Come visit Uromedica in Milan on March 10-13 at the European Association of Urology (EAU) meeting, Booth A05.

Uromedica at SUFU Nashville 2023

Come visit Uromedica in Nashville March 7 – 11, at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting!

Uromedica at AUA 2022

Come visit Uromedica at Booth 2719 in New Orleans for the American Urological Association (AUA) meeting!

New ProACT Paper: Bada et al

New OUS ProACT Paper: ProACT in the management of stress urinary incontinence after radical prostatectomy. What happens after 8 years of follow up? Monocentric analysis in 42 patients.

New CPT-I codes for ProACT

Four new Category I CPT codes have been assigned to ProACT™ Adjustable Continence Therapy for Men and will be effective January 1st, 2022.

Uromedica at AUA 2021

Come visit Uromedica at Booth 431 in Las Vegas for the American Urological Association (AUA) meeting!

First Patients Enrolled in ACT Trial

First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial

New ProACT Surgical Video

New surgical video for the ProACT Adjustable Continence Therapy for Men.

New ProACT Animation

New animation on the ProACT Adjustable Continence Therapy for Men procedure.

New ProACT Paper: Munier et al

New OUS ProACT Paper: What if artificial urinary sphincter is not possible? Feasibility and effectiveness of ProACT for patients with persistent stress urinary incontinence after radical prostatectomy treated by sling

ACT Clinical Trial

FDA Approval on the Protocol for the Clinical Investigation on the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence

ProACT receives French National Reimbursement

ProACT is now listed on the LPPR register and reimbursed in France.

New ProACT Paper: Larson et al

New USA ProACT Paper: Adjustable continence therapy (ProACT) for the treatment of male stress urinary incontinence: A systematic review and meta-analysis

New ProACT Paper: Nash et al

New USA ProACT Paper: Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial.

First US Commercial Implant of ProACT

Uromedica Announces Successful First US Commercial Implant of ProACT™ Adjustable Continence Therapy for Men

Launch of ProACT and Reimbursement Coding

Uromedica Announces Launch of ProACT™ Adjustable Continence Therapy for Men with FDA Approval and Reimbursement Coding

French Randomized Trial Between ACT and AMS 800 AUS

First patients enrolled in French Randomized Trial Between Uromedica’s Adjustable Continence Therapy (ACT) and Boston Scientific’s AMS 800 Artificial Urinary Sphincter (AUS)

New ProACT Paper: Reuvers et al

New ProACT Paper in Urology: Maximum Urethral Closure Pressure Increases After Successful Adjustable Continence Therapy (ProACT) for Stress Urinary Incontinence After Radical Prostatectomy by Reuvers et al.

ProACT PMA Approved by USA FDA

Uromedica's ProACT Adjustable Continence Therapy for Men receives PMA Approval from the USA Food and Drug Administration (FDA)